# US 12,213,952 B1 · Biologic enhancement formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,213,952 B1
- Document ID: US12213952B1
- Status: Granted
- Kind: B1
- Application number: 18/412,174
- Filed: 2024-01-12
- Granted: 2025-02-04
- Earliest claimed: 2017-03-09
- Assignees: Heh Research & Development Services, Inc.
- Applicants: Heh Research & Development Services, Inc.
- Inventors: Stephen J. Harkins; Mitchell R. Halter
- Web page: https://patentgrep.com/patent/US12213952B1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A23L 2/56: Flavouring or bittering agents (sweeteners A23L2/60)
- A23L 2/60: Sweeteners
- A23L 33/155: Vitamins A or D
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided is an “all natural” biologic-enhancing beverage (BioBeverage), which contains, in addition to purified water, electrolytes, vitamins, anti-oxidants, micronutrients, natural fruit infusion, natural sweetener to improve taste, enhance GI Biome viability, provide antimicrobial benefits and reduce oxidative stress, Citicoline, to enhance brain/neurologic function, neurologic maintenance, repair and regeneration, CoQ10, to enhance cardiovascular energy and health, Hydroxyproline, to enhance connective tissue maintenance, repair and regeneration, and a niacinamide adenine dinucleotide (NAD+) precursor to promote overall health, including neurologic, cardiovascular and connective tissues maintenance and repair, and if present, reduce risks and symptoms of multiple neurodegenerative disorders by maintenance of healthy mitochondrial function.

## Claims

### Claim 1

A method for reducing symptoms of a disease in an individual in need thereof which method comprises administering to the individual a therapeutically effective amount of a ingestible formulation comprising Citicoline, CoQ10, hydroxyproline, and a niacinamide adenine dinucleotide (NAD+) precursor wherein the disease is a neurological disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurological disease is a neurodegenerative disorder, and the formulation is administered twice daily.

### Claim 3 (depends on 1)

The method of claim 1, wherein the formulation is administered as a liquid or suspension in a liquid carrier.

### Claim 4 (depends on 2)

The method of claim 2, wherein the liquid carrier comprises water.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease is an infectious neurological disease cause by spirochetes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the neurological disease is Lyme Disease or Syphilis.